Oncology Revenue Surges 16% as New Launches Offset Farxiga Generics (AZN Q1 2026 Earnings Call)

By Dr. Graph | Updated on May 6, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

AstraZeneca's first-quarter performance highlighted the resilience of its diversified portfolio, as accelerating demand in oncology and rare diseases successfully absorbed the long-anticipated generic competition for its blockbuster diabetes drug. The company's heavy investment in research and development is yielding significant pipeline successes, positioning the firm to manage near-term exclusivity losses while establishing a foundation for sustained growth through the end of the decade.

Oncology Franchise Drives Overall 8% Revenue Expansion

Total revenue increased by 8% year-over-year as demand for innovative medicines offset patent expirations. The oncology segment served as the primary growth engine, surging 16% to $6.8 billion due to exceptional adoption across the United States and Europe. This top-line momentum cascaded down the income statement, generating a 12% expansion in core operating profit which highlights the company's strong operating leverage.

Enhertu and Imfinzi Accelerate Despite Tagrisso Destocking

Within the cancer portfolio, the immuno-oncology franchise anchored by Imfinzi delivered exceptional 30% growth as new indications gained rapid clinical acceptance. The targeted therapy Enhertu surged 34% year-over-year, validating its expanded use in treating patients with low HER2 expression. While Tagrisso revenues grew only 5%, Executive Vice President David Fredrickson clarified that underlying United States demand grew in the mid-teens before being temporarily depressed by higher-than-historical wholesaler destocking.

Rare Disease Portfolio Thrives While Cardiovascular Faces Headwinds

The Rare Disease division expanded 15% year-over-year, driven by strong patient demand and global geographic expansion. Conversely, the Cardiovascular, Renal and Metabolism group declined 6% as expected generic competition began eroding established market shares. This contraction was primarily driven by a 3% decline in Farxiga following its loss of exclusivity in several international markets and the anticipated entry of generic competitors in the United States.

Pipeline Successes Set Stage for Next Generation of Blockbusters

The company announced positive results from four high-value Phase III programs during the quarter, increasing confidence in its medium-term revenue replacement strategy. Executive Vice President Sharon Barr highlighted the comprehensive LUNA program for tozorakimab in chronic obstructive pulmonary disease, which demonstrated clinically meaningful exacerbation reductions across a broad patient population. Similarly, the rare disease segment reported positive Phase III data for efzimfotase alfa, advancing a next-generation enzyme replacement therapy with a more patient-friendly dosing profile.

Frequently Asked Questions

What caused the seemingly slow 5 percent growth rate for Tagrisso in the first quarter?

Executive Vice President David Fredrickson explained that while the net growth was 5 percent, underlying United States demand actually grew in the mid-teens. The reported figure was pulled down by temporary, higher-than-historical wholesaler destocking rather than a drop in patient demand.

How is AstraZeneca managing the loss of exclusivity for Farxiga?

The company is offsetting the 3 percent decline in Farxiga revenues through robust performance in its other divisions. Executive Vice President Ruud Dobber noted that despite generic entrants in the United States starting in April, growth in key respiratory brands and the upcoming launch of baxdrostat are helping stabilize the broader biopharmaceuticals portfolio.

What makes the recent Phase III data for tozorakimab significant for the respiratory market?

Executive Vice President Sharon Barr stated that tozorakimab achieved statistically significant reductions in moderate to severe exacerbations across a broad population, distinguishing itself from current biologics by showing efficacy regardless of eosinophil levels or smoking status.